What hides behind the MASC: Clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)

Drilon, A.; Li, G.; Dogan, S.; Gounder, M.; Shen, R.; Arcila, M.; Wang, L.; Hyman, D. M.; Hechtman, J.; Wei, G.; Cam, N. R.; Christiansen, J.; Luo, D.; Maneval, E. C.; Bauer, T.; Patel, M.; Liu, S. V.; Ou, S. H. I.; Farago, A.; Shaw, A.; Shoemaker, R. F.; Lim, J.; Hornby, Z.; Multani, P.; Ladanyi, M.; Berger, M.; Katabi, N.; Ghossein, R.; Ho, A. L.

Published in

Elsevier, Annals of Oncology, 5(27), p. 920-926, 2016

DOI: 10.1093/annonc/mdw042

Tools

Export citation

Search in Google Scholar

What hides behind the MASC: Clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)

Journal article published in 2016 by A. Drilon, G. Li, S. Dogan, M. Gounder, R. Shen, M. Arcila, L. Wang, D. M. Hyman, J. Hechtman, G. Wei, N. R. Cam, J. Christiansen, D. Luo, E. C. Maneval, T. Bauer

and other authors.

This paper is available in a repository.

Full text: Download

Preprint: archiving allowed

Upload

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by

Published in

Links

Tools

What hides behind the MASC: Clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)